* Maxx Orthopedics has announced the latest addition to its expanding Libertas® Hip Portfolio, securing FDA 510(k) clearance for the Libertas® Bipolar Hip System. This development further broadens the company's suite of hip solutions, which already features the Libertas® Taper Reduced (TR) Stems, Libertas® Mini TR Stems designed for anterior approaches, Libertas® HA Coated Stems available in collared and non-collared options, and the Libertas® Cemented Stems. The newly cleared Bipolar System enhances the offering available to surgeons looking for flexible, clinically validated options for hemiarthroplasty procedures.
NORRISTOWN, Pa. -- Maxx Orthopedics, Inc., a fast-growing global medical device manufacturer based in Norristown, Pennsylvania, has confirmed US FDA clearance for the Libertas® Bipolar Hip System.
The approval marks another significant milestone for the company, expanding the established Libertas® Hip Portfolio and reinforcing its commitment to delivering innovative and reliable solutions for orthopaedic surgeons. With the addition of the Bipolar System, Maxx Orthopedics strengthens its position as a provider of comprehensive hip reconstruction technologies aimed at improving clinical outcomes in hemiarthroplasty.
The Libertas® Bipolar System combines a cobalt-chromium (CoCr) outer shell with an ultra-high molecular weight polyethylene (UHMWPE) liner and a factory-assembled retention ring. Designed for use with 28 mm femoral heads, the system delivers a reliable, efficient, and reproducible solution for fracture management, osteonecrosis, and revision hip applications.
Key Features and Benefits:
* 28mm Head Compatibility – Streamlined solution designed exclusively for 28 mm femoral heads, simplifying complexity in head selection and optimizing intraoperative efficiency.
* Comprehensive Sizing – Offered in 44–60 mm diameters (1 mm increments) to accommodate a wide range of patient anatomies.
* Proven Materials – CoCr outer shell with UHMWPE liner and retention ring deliver durability and stability.
* Self-Aligning Design – Eccentric head geometry and preassembled liner ensure smooth articulation and a secure fit.
* Modern Instrumentation – Includes trial heads, sizing gauges, and extraction tool in a dedicated bipolar instrument set for streamlined surgical workflow.
"We are proud to expand our hip portfolio with the FDA clearance of the Libertas® Bipolar System," said Farzin Khaghani, Chief Commercial Officer at Maxx Orthopedics. "This addition demonstrates our ongoing commitment to supporting surgeons with advanced implant options and instrumentation that address diverse patient needs. Our focus remains on innovation that drives creative, affordable, reliable, and efficient solutions."
source:newsreleases.co.uk
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval